Reversal Agents: What We Have and What We Can Expect

Clinical trials in patients with atrial fibrillation have demonstrated that non-vitamin K antagonist oral anticoagulants [novel oral anticoagulants (NOACs)] are markedly safer than warfarin with respect to serious bleeding—especially intracranial hemorrhage, the most feared and devastating complicat...

Descripción completa

Detalles Bibliográficos
Autor principal: Ruff, Christian T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MediaSphere Medical 2018
Materias:
Research Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252789/
https://www.ncbi.nlm.nih.gov/pubmed/32477806
http://dx.doi.org/10.19102/icrm.2018.090403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252789/
https://www.ncbi.nlm.nih.gov/pubmed/32477806
http://dx.doi.org/10.19102/icrm.2018.090403

Ejemplares similares